Timber pharmaceuticals announces fda grant of carc waiver for tmb-001

- phase 3 ascend study of tmb-001 (topical isotretinoin) for the treatment of congenital ichthyosis is 70% enrolled -
TMBR Ratings Summary
TMBR Quant Ranking